P3 Health Partners Announces $70M Preferred Stock and Warrant Financing

What Happened P3 Health Partners Inc. (PIII) filed an 8‑K reporting that on September 8, 2026 it entered into a Securities Purchase Agreement to issue up to $70 million of Units in multiple tranches to affiliates of Chicago Pacific Founders (CPF). Each Unit includes shares of newly created Series D‑1 19.5% Cumulative Preferred Stock and warrants to purchase Class A Common Stock. The Company also entered a Registration Rights Agreement to register shares issuable on exercise of the warrants (subject to any Nasdaq shareholder approvals) and a Fourth Amended and Restated Letter Agreement with CPF affiliates that affects board designation, information rights, protective provisions and a standstill extension.

Key Details

• Total commitment: up to $70,000,000 of Units (multiple tranches) under a Purchase Agreement dated September 8, 2026.
• Series D‑1 preferred: 19.5% cumulative dividend rate, stated value $100 per share, non‑convertible, non‑voting, not listed, redeemable at $100 plus accrued unpaid dividends, ranks senior to common stock for dividends and liquidation.
• Warrants: exercisable for a number of Class A Common shares equal to 0.66333% of outstanding Class A and Class V common per $1,000,000 funded; exercise price = Nasdaq Minimum Price on issuance date; 7‑year term.
• Governance and restrictions: CPF affiliates may designate one additional independent director while they own 40% of outstanding common; CPF gains certain information/protective rights; CPF agreed to extend a standstill limiting ownership to 49.99% through December 31, 2027.
• Transaction approvals: A special independent board committee negotiated and approved the related‑party transactions; securities were sold in a private placement to accredited investors relying on Section 4(a)(2).

Why It Matters This financing provides P3 Health with fresh capital (up to $70M) but introduces high‑rate preferred stock that takes priority over common stock for dividends and liquidation and carries a high 19.5% cumulative dividend—an important cash/financial commitment. The attached warrants could dilute common shareholders if exercised, and CPF’s governance rights (board designation while owning 40%) increase their influence. The Registration Rights Agreement may allow resale of warrant‑issued common shares once registered, which could affect share supply. Investors should weigh the capital benefit against potential dilution and changes in governance.